NextFin News - Novo Nordisk raised its full-year outlook and beat third-quarter profit estimates on Wednesday, as sales of its once-daily Wegovy pill came in roughly 17% above what analysts had forecast and gave investors their clearest evidence yet that the obesity-drug leader can grow its way out of a brutal pricing squeeze.
The Danish drugmaker said adjusted sales of DKK 79.2 billion rose 4% at constant exchange rates in the third quarter, ahead of the DKK 73.2 billion consensus, while adjusted operating profit of DKK 31.7 billion jumped 27% at constant currency against a depressed year-ago base. Management now expects adjusted sales and adjusted operating profit to be flat to up 2% in 2026, a meaningful lift from the flat to down 6% range it guided after the second quarter. Wegovy in pill form alone generated DKK 5.4 billion in the quarter, versus a consensus of DKK 4.6 billion, and had reached eight markets by the end of September after launching in the United States, the UAE, the UK and Germany.
The question the quarter forces investors to answer is not whether Wegovy still sells - it clearly does - but whether the pill changes the economics of the weight-loss drug war. For most of 2026, Novo's story was a defensive one: compounded copycats and U.S. pricing pressure eroding a franchise. The pill flips that script by expanding who can be treated, how they stay on treatment, and how aggressively Novo can price against Eli Lilly's competing oral candidate without destroying margins. The market is starting to price that possibility back in.
The Numbers: A Beat Built on the Pill, Not a One-Off
The headline operating-profit print needs one adjustment before it can be read. Reported operating profit fell 9% at constant currency to DKK 23.0 billion, dragged down by DKK 8.7 billion of non-cash impairment charges - DKK 4.6 billion tied to the cardiovascular candidate ziltivekimab and DKK 4.1 billion to right-sizing the manufacturing network. Strip those out, and the underlying engine is what moved: adjusted operating profit up 27% at CER, on adjusted sales up 4% at CER.
Three figures carry the story. First, the guidance revision: adjusted sales and operating profit growth for 2026 is now expected to be -2% to +2% at constant exchange rates, up from 0% to -6% set after the second quarter. Second, the pill: DKK 5.394 billion of Q3 Wegovy-pill sales, about 17% above the DKK 4.6 billion analysts had penciled in. Third, the trajectory embedded in the nine-month figures: adjusted sales of DKK 227.7 billion were flat in kroner but up 2% at CER, meaning the second-half acceleration is real rather than a single-quarter pop.
The beat was broad enough to matter. Obesity-care volume growth drove both U.S. and international operations, and the company said Wegovy holds more than half of new-patient starts in the branded obesity market. Ozempic in pill form, launched in the U.S. in May, is also contributing: weekly new-to-brand prescriptions are running about 100% above the pre-launch levels the Rybelsus brand carried.
Growth was led by our obesity portfolio, with continued uptake of Wegovy pill in the US and encouraging early launches internationally. Our focus is on sustaining this progress through disciplined execution and broader access to our medicines. We are also advancing our pipeline and preparing for the US launch of CagriSema in early 2027, subject to regulatory approval. Mike Doustdar, Novo's president and chief executive
That last clause - CagriSema, the once-weekly combination of semaglutide and cagrilintide - is the second half of the answer. The pill defends the present; CagriSema is meant to win the next round. In the REDEFINE 9 trial, the 1.0/1.0 mg dose delivered 21% weight loss at week 68 versus 2.0% for placebo. In REIMAGINE 5, adults with type 2 diabetes and obesity lost 12.4% on CagriSema versus 9.1% on tirzepatide 5 mg, while matching Lilly's drug on HbA1c reduction. The FDA is expected to rule on the weight-management application in the fourth quarter, with a U.S. launch targeted for early 2027.
Why the Pill Is a Structural Shift, Not Just a New Dosage Form
The most important number in this report is not the earnings beat. It is the 16.6%.
In the OASIS 4 phase 3 trial, adults with overweight or obesity taking oral semaglutide 25 mg lost an average of 16.6% of body weight over 64 weeks, versus 2.7% on placebo, when measured on the on-treatment estimand. Even on the more conservative treatment-policy read - counting patients regardless of whether they stayed on therapy - weight loss was 13.6% versus 2.4%. More than half of patients, 56.1%, lost at least 15% of body weight. That efficacy profile sits close to the injectable Wegovy that made Novo the most valuable company in Europe, and it is delivered in a tablet.
This is the mechanism behind the guidance raise, and it is structural rather than cyclical. A cyclical recovery would mean existing patients returning as compounding pressure fades. What the pill does is different: it expands the treatable population at the margin. Patients who refused needles, who travel, who fear refrigeration or sharps disposal, or who simply prefer a daily ritual to a weekly injection become addressable. Novo itself has framed the pill as a tool for adherence, and early real-world data support the point - in the OCTANE study of adults switching from injectable GLP-1s to the oral formulation, patients lost a further 4.1% of body weight over three months, meaning the pill can retain, not just recruit.
The second structural lever is global scale. By the end of the quarter the pill was on the market in the US, UAE, UK and Germany; four more countries have followed, taking the total to eight. Injections require cold-chain logistics, trained administration and clinical waste handling. Tablets do not. That difference matters more outside the United States, where specialist obesity infrastructure is thinner and primary-care prescribing is the growth engine. The pill is not merely a convenience product; it is a distribution technology.
And there is a third lever, the one Wall Street is only beginning to price: the pill gives Novo a weapon in the price war. The company has said it will cut U.S. list prices for Ozempic and Wegovy by up to 50% starting in 2027, to $675 a month. A price cut on an injectable with constrained manufacturing capacity is margin-destructive. The same cut on a pill, with higher throughput and lower administration friction, can be volume-accretive. The strategy is to trade list price for covered lives - and coverage, not efficacy, is what has capped GLP-1 penetration in the United States.
The Counter-Thesis: Margins, Cannibalization and Lilly's Answer
The bullish read is clean. The bear case is not trivial, and it attacks the heart of the thesis: that the pill restores profitable growth rather than simply shifting sales from one Novo product to another while compressing margins.
Citigroup, which cut its price target on Novo to DKK 296 from DKK 310 after the company's Capital Markets Day, argues that management's guidance for broadly stable margins through 2030 leaves little room for multiple expansion. The bank trimmed its adjusted operating-profit forecasts for 2028 through 2030 by 2% to 4%, even as it raised its 2026 and 2027 estimates by 2% to 3% on stronger pill sales. The Citi view is that the GLP-1 market is becoming a volume business with pharmaceutical economics, not a scarcity business with luxury-goods margins - and that Novo's own price cuts will accelerate that transition.
There is also the cannibalization question. Every Wegovy pill prescription is, at the margin, a prescription that might otherwise have been an injection. If the pill merely migrates existing patients to a cheaper-to-make but lower-list-price product, top-line growth could hold while profit per patient falls. Novo's defense is that the net effect is additive - the OCTANE switch data and the roughly 89% share of U.S. prescriptions for the two once-daily oral obesity medicines, versus about 11% for Lilly's Foundayo per IQVIA data for the week ended July 3, suggest the pill is winning share from competitors as well as converting internal patients. But the mix shift is real, and it will show up in gross margin before it shows up in revenue.
Then there is Lilly. The Indianapolis-based rival is not standing still. Its oral GLP-1 candidate, orforglipron, has posted strong phase 3 results in type 2 diabetes, and the company has claimed superiority over oral semaglutide 14 mg on both A1c and weight loss at the highest doses. Lilly's Foundayo already competes directly with the Wegovy pill in the U.S., and its injectable Zepbound continues to take obesity share. The GLP-1 duopoly is real, but duopolies still compete - on price, on coverage, and on the next molecule.
The strongest version of the bear case, then, is this: Novo has won the first oral race and lifted 2026 guidance, but it has simultaneously locked itself into a lower-margin, higher-volume market where Lilly is equally well armed, and where the 27% operating-profit pop this quarter is partly a favorable comparison base from DKK 9 billion of transformation costs in the year-ago period. On that read, the pill is a good product in a deteriorating pricing environment, and the guidance raise is a floor, not a launchpad.
The signal that would prove the bull case wrong is specific and observable: if Wegovy-pill sales growth decelerates materially in the fourth quarter while U.S. realized prices for the GLP-1 portfolio fall faster than the company's 2027 list-price reductions can offset, adjusted operating-profit growth for 2026 would land at the low end of the new -2% to +2% range rather than the upper half management is implying. Watch the next quarterly report for the gap between volume growth and realized-price decline - a widening spread is the early-warning light.
What This Means Across Time Horizons
Short term (sentiment and positioning): The shares had been climbing into the print - up about 4% from the October 3 close through November 3, per market data - and the stock rose in early trading on the day of the results. The immediate catalyst is the guidance midpoint moving from -3% to 0%, which removes the recession-style earnings narrative that had kept the multiple compressed. NVO closed the prior session at $40.19 in New York, down 0.64%, and at DKK 270.15 in Copenhagen, essentially flat, giving the market room to re-rate on the new outlook.
Medium term (fundamentals, 2027): The base case is that the pill contributes high-single-digit to low-double-digit growth through 2027 as it rolls into more markets and coverage expands, while CagriSema adds a second growth vector if approved. The upside case requires the price-for-coverage trade to work: list-price cuts unlock Medicare and commercial formulary access, volume surges, and operating profit grows faster than sales as manufacturing scales. The downside case is the Citi scenario: margins stabilize but do not expand, the pill cannibalizes injections faster than it recruits new patients, and the stock remains a value trap despite growing earnings.
Long term (structural): This is where the cyclical-versus-structural call resolves. The pricing pressure that battered Novo through 2025 and early 2026 is cyclical - driven by policy scrutiny, the 340B drug-pricing program, and the temporary availability of compounded alternatives, all of which mean-revert as regulation tightens and branded access improves. The oral platform, by contrast, is structural: it permanently lowers the barrier to treatment and shifts GLP-1 therapy from specialist-administered injection to primary-care-prescribed tablet. If that read is right, the 2026 trough is the inflection, not the pause before the next leg down.
The practical implication for the broader market is a rotation within the obesity complex rather than a sector-wide rerating. Suppliers of injection devices and cold-chain logistics face a slower growth path; primary-care channels, telehealth platforms and pharmacy-benefit managers that can distribute at scale stand to gain. For investors holding both Novo and Lilly, the quarter argues for owning the duopoly and letting the price war play out - the company that converts the most newly addressable patients, not the one with the marginally better molecule, will compound fastest over the next cycle.
What to Watch Next
Three data points will separate the bull case from the bear case over the next two quarters. First, fourth-quarter Wegovy-pill sales and the pace of international launches beyond the initial eight markets. Second, the realized-price trajectory in the U.S. GLP-1 portfolio relative to the announced 2027 list-price cuts - the spread between volume growth and price decline is the margin tell. Third, the FDA decision on CagriSema for weight management, expected in the fourth quarter, and any read-through from Lilly's oral orforglipron data.
The earnings call is set for 13:00 CET on November 4, where management will be pressed on whether the new guidance assumes the pill's momentum holds through the holiday prescribing season and how much of the 2027 price reduction is already reflected in payer negotiations.
Novo did not just beat estimates on Wednesday - it changed the shape of the earnings curve. The pill converts a pricing problem into a volume opportunity, but only if the volume arrives fast enough to outrun the price cuts. This quarter says it might.
Explore more exclusive insights at nextfin.ai.
